NEW YORK, Feb. 28 (GenomeWeb News) - Affymetrix shares were down 9.1 percent,or $3.58, at $35.77 in afternoon trade amid general weakness in drug stocks and following an SEC filing in which the company said that "the market for whole genome mapping products has temporarily slowed."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.